Posted On: 04/19/2016 10:03:09 AM
Post# of 876
Wolverine Technologies Signs Share Purchase Agreement with Dr. David Chalk
Vancouver, British Columbia--(Newsfile Corp. - April 19, 2016) - Wolverine Technologies Corp. (OTCQB: WOLV) ("Wolverine" ) has signed a Share Purchase Agreement with Dr. David Chalk, a director of Wolverine, whereby Dr. Chalk will invest, one-third of the net proceeds received by Dr. Chalk from the sale of Dr. Chalk's 15% interest in Decision-Zone Inc. ("DZI" ), in a private placement of 400,000,000 common shares of Wolverine. DZI is a potential acquisition target by a major technology company.
Overview of Decision-Zone Inc. and DZAudit
DZI is the leading developer of next generation cyber security and business efficiency technology. DZI developed and patented the DZAudit technology. The patent for DZAudit was issued on March 15, 2011, see link below this commentary. The patent explains that to detect anomalies, current approaches evaluate transaction data statistically and to validate whether the transaction is indeed anomalous requires significant storage, processing power and human resources. The new approach (DZAudit) audits events as they happen against the business process definition. Events that do not follow the right sequences and conditions of the process definition are identified to be anomalous. Current audit methodologies are not automated and have a big latency factor that precludes them from being used for real time transactional validation.
http://tinyurl.com/zaawahs
The proceeds from the sale of Dr. Chalk's interest in DZI and subsequent private placement will be used by Wolverine to acquire and develop new leading edge technologies.
On behalf of the Board
Richard Haderer
CEO
For further information please contact:
Investor Relations (778) 297-4409
mailto:investor@wolverinetechnologiescorp.com
http://www.wolverinetechnologiescorp.com
Or
US Investor Relations
1-800-969-2605
Vancouver, British Columbia--(Newsfile Corp. - April 19, 2016) - Wolverine Technologies Corp. (OTCQB: WOLV) ("Wolverine" ) has signed a Share Purchase Agreement with Dr. David Chalk, a director of Wolverine, whereby Dr. Chalk will invest, one-third of the net proceeds received by Dr. Chalk from the sale of Dr. Chalk's 15% interest in Decision-Zone Inc. ("DZI" ), in a private placement of 400,000,000 common shares of Wolverine. DZI is a potential acquisition target by a major technology company.
Overview of Decision-Zone Inc. and DZAudit
DZI is the leading developer of next generation cyber security and business efficiency technology. DZI developed and patented the DZAudit technology. The patent for DZAudit was issued on March 15, 2011, see link below this commentary. The patent explains that to detect anomalies, current approaches evaluate transaction data statistically and to validate whether the transaction is indeed anomalous requires significant storage, processing power and human resources. The new approach (DZAudit) audits events as they happen against the business process definition. Events that do not follow the right sequences and conditions of the process definition are identified to be anomalous. Current audit methodologies are not automated and have a big latency factor that precludes them from being used for real time transactional validation.
http://tinyurl.com/zaawahs
The proceeds from the sale of Dr. Chalk's interest in DZI and subsequent private placement will be used by Wolverine to acquire and develop new leading edge technologies.
On behalf of the Board
Richard Haderer
CEO
For further information please contact:
Investor Relations (778) 297-4409
mailto:investor@wolverinetechnologiescorp.com
http://www.wolverinetechnologiescorp.com
Or
US Investor Relations
1-800-969-2605
(0)
(0)
